biomea fusion Revenue and Competitors

Location

#8280

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • biomea fusion's estimated annual revenue is currently $7.8M per year.(i)
  • biomea fusion's estimated revenue per employee is $61,508
  • biomea fusion's total funding is $56M.
  • biomea fusion's current valuation is $262.3M. (January 2022)

Employee Data

  • biomea fusion has 126 Employees.(i)
  • biomea fusion grew their employee count by 25% last year.

biomea fusion's People

NameTitleEmail/Phone
1
Founder, Chairman & CEOReveal Email/Phone
2
Chief People OfficerReveal Email/Phone
3
EVP ChemistryReveal Email/Phone
4
VP, Corporate ControllerReveal Email/Phone
5
EVP, Intellectual PropertyReveal Email/Phone
6
VP Clinical OperationsReveal Email/Phone
7
VPReveal Email/Phone
8
SVP Corporate Development- Head Business DevelopmentReveal Email/Phone
9
VP, Medical AffairsReveal Email/Phone
10
VP, Clinical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is biomea fusion?

Biomea Fusion, Inc. was formed in 2017 by a small group of biotech executives. We are dedicated to developing innovative medicines for patients. It is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. The more precise a therapeutic agent is, the better the potential outcomes for individual patients' needs. We are a precision oncology company developing novel small molecules that target aggressive forms of cancer. Patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. With our current program, we are targeting specific changes to the DNA of patients, which can be isolated as key drivers for tumor growth. We leverage our in-house drug design and operational expertise to create novel small molecules against genetically defined forms of cancer. Our goal is to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful medicines for patients in need.

keywords:N/A

$56M

Total Funding

126

Number of Employees

$7.8M

Revenue (est)

25%

Employee Growth %

$262.3M

Valuation

N/A

Accelerator

biomea fusion News

2022-04-19 - Biomea Fusion Announces Acceptance of Multiple Abstracts at the 2022 ASCO Annual Meeting

Biomea Fusion, Inc. Biomea to present preclinical data in chronic lymphocytic leukemia (CLL) and Trial In Progress (TIP) information for its...

2022-04-19 - Biomea Fusion Announces Acceptance of Multiple Abstracts ...

REDWOOD CITY, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company...

2022-03-30 - Biomea Fusion Reports Preclinical Data on BMF-219 and Trial ...

REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company...

2021-01-06 - Biomea Fusion Raises $56 Million Series A

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of a $56 million Series A financing today. The syndicate is ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.9M1279%N/A
#2
$41.3M12814%N/A
#3
$18.9M13081%$166M
#4
$37.7M13010%N/A
#5
$19M131N/AN/A